# OnCo record tolremo-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/tolremo-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "tolremo-therapeutics" ;
  schema:name "TOLREMO therapeutics"@en ;
  schema:alternateName "TOLREMO therapeutics AG"@en, "Tolremo"@en ;
  schema:description "TOLREMO therapeutics makes TT125-802, a tablet drug that blocks the proteins CBP and p300, which cancer cells use to switch on genes that let them resist targeted treatments. Its first trial, in advanced solid tumours, showed tumour shrinkage in some people with drug-resistant lung cancer."@en ;
  schema:url <https://onco.cc/companies/tolremo-therapeutics/>, <https://www.tolremo.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.tolremo.com/>, <https://www.tolremo.com/press-releases/2026/09/15/tolremo-therapeutics-completes-phase-i-study-of-tt125-802-and-presents-final-clinical-data-at-world-conference-on-lung-cancer-2026>, <https://clinicaltrials.gov/study/NCT06403436> ;
  schema:addressCountry "CH" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/epigenetics/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/> ;
  onco:targets <https://onco.cc/targets/crebbp/>, <https://onco.cc/targets/ep300/> .